Poly-Vitamin Chewable Tablets w/Fluoride Rx
Generic Name and Formulations:
Vit. A 2500 IU, thiamine 1.05mg, riboflavin 1.2mg, niacin 13.5mg, pyridoxine 1.05mg, Vit. B12 4.5mcg, folic acid 0.3mg, Vit. C 60mg, Vit. D 400 IU, Vit. E 15 IU, fluoride (as sodium) 0.25mg, 0.5mg, 1mg; chew tabs; assorted orange, grape, and cherry flavors.
Various generic manufacturers
Indications for Poly-Vitamin Chewable Tablets w/Fluoride :
Nutritional supplement, prevention of dental caries where water fluoridation <0.6ppm.
Base dose on fluoride content of water. <4yrs: use drops. <6mos: not recommended. If fluoride content <0.3ppm: 6mos–3yrs: 0.25mg fluoride/day; 3–6yrs: 0.5mg fluoride/day; 6–16yrs: 1mg fluoride/day. If fluoride content 0.3–0.6ppm: 6mos–3yrs: not recommended; 3–6yrs: 0.25mg fluoride/day; 6–16yrs: 0.5mg fluoride/day.
Water fluoridation >0.6ppm.
Dental fluorosis in chronic overdosage. Account for other sources of flouride.
Insoluble calcium fluoride with dairy products.
Formerly known under the brand name Poly-Vi-Flor.
Sign Up for Free e-newsletters
- Managing Chemo Brain in Pediatric Survivors of Childhood Cancer
- Aggressive Therapy Provides No Additional Advantage in Metastatic Prostate Cancer
- Excretion of Volatile Organic Compounds Higher in AYAs Using Vaping Products
- FDA, ASHP Actions to Prevent or Manage Chemotherapy Drug Shortages
- Risk for Cardiovascular Disease Higher in Survivors of Testicular Cancer
- Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer
- Cost vs Benefits: The Controversy Over Proton Beam Radiotherapy
- Patient Expectations at Odds With Actual Outcomes for Radiotherapy in Breast Cancer
- Patients Desire More Online Tools and Access
- Metformin Plus Ruxolitinib: A Potential Therapeutic Alternative for Myeloproliferative Neoplasms
- Sexual Quality of Life Decreased During, After Chemotherapy for Digestive Cancers
- CHEMO-SUPPORT: A Nursing Intervention to Relieve Chemotherapy Symptom Burden
- Approach and Management of Checkpoint Inhibitor-related Immune Hepatitis
- Revised AJCC8 Demonstrates Superior Tumor Classification for HNCSCC
- Oral Androgen Receptor Inhibitor Granted FDA Approval for Nonmetastatic CRPC
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|